Over the last seven years, seven targeted agents have been approved in the treatment of advanced or metastatic renal cell cancer, changing the therapeutic approach and prognosis of the disease dramatically. The latest agent with demonstrated efficacy is axitinib (Inlyta(®)). This new generation of tyrosine kinase agent differs from previously existing agents by its greater activity potency of inhibition of vascular endothelial growth factor-receptor (VEGFR1-3). This efficacy has been tested in phase II and III clinical trials. Axitinib is the only targeted agent that benefits from recommended titration, with intra-patient dose escalation. The toxicity profile of the drug is tolerable. This paper reviews the mechanism of action of axitinib, its metabolism, and its pharmacokinetic profile. Clinical data of efficacy and safety is also detailed. The agent has been integrated in the international therapeutic guidelines, as a standard in treatment of renal cell cancer patients, previously treated through antiangiogenic therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825605 | PMC |
| http://dx.doi.org/10.4137/CMO.S10594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Naringenin Inhibits Ferroptosis in Renal Tubular Epithelial Cells of Diabetic Nephropathy Through SIRT1/FOXO3a Signaling Pathway.
Drug Dev Res
February 2025
Graduate School, Fujian University of Traditional Chinese Medicine, Fuzhou City, People's Republic of China.
Naringenin has the potential to regulate ferroptosis and mitigate renal damage in diabetic nephropathy (DN). However, it remains unclear whether the naringenin's effects in DN are linked to its ability to regulate ferroptosis. This study investigated the potential anti-ferroptosis properties of naringenin in high glucose (HG)-induced renal tubular epithelial cell models.
View Article and Find Full Text PDFThe relationship of irisin, apelin-13, and immunological markers il-1α & amp, il-1β with diabetes in kidney failure patients.
Cell Mol Biol (Noisy-le-grand)
January 2025
Biochemistry Department, College of Medicine, Tikrit University, Tikrit, Iraq.
Chronic kidney disease (CKD) is often complicated by diabetes, impacting various biochemical and immunological markers. This study aimed to investigate the relationship between irisin, apelin-13, and immunological markers IL-1α and IL-1β in diabetic patients with CKD. This cross-sectional study was conducted from January to June 2023 in a tertiary care hospital in Tikrit City, Iraq.
View Article and Find Full Text PDFRenal Tubular Epithelial Cell-Derived hsa_circ_0008925 From Urine Is Related to Chronic Renal Fibrosis.
J Cell Mol Med
January 2025
Department of Nephrology, Yi Ji Shan Hospital Affiliated to Wan Nan Medical College, Wuhu, Anhui, China.
Renal fibrosis (RF) is a crucial pathological factor in the progression of chronic kidney disease (CKD) to end-stage renal failure, and accurate and noninvasive assays to monitor the progression of renal fibrosis are needed. Circular RNAs (circRNAs) are noncoding RNAs that can be used as diagnostic biomarkers and therapeutic targets for human diseases. In this study, we analysed the expression of hsa_circ_0008925 in human urinary renal tubular cells and investigated its role in renal fibrosis.
View Article and Find Full Text PDFUnveiling the risks: protecting privacy in single-cell genomics data.
Nephrol Dial Transplant
January 2025
Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.
Unraveling diabetic kidney disease: insights from single-cell RNA sequencing.
Int Urol Nephrol
January 2025
Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
The incidence of diabetic kidney disease (DKD) is rising annually. Diabetes leads to structural damage and dysfunction in the kidneys, clinically manifesting as progressive proteinuria and declining renal function, ultimately resulting in end-stage renal disease (ESRD). Recent findings have identified a subset of DKD known as normoalbuminuric diabetic kidney disease (NADKD), characterized by normal urine albumin levels but reduced renal function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!